Charles W. Newhall III

Executive

Director

Insider activity · 24 months0 buys4 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 3 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 1 saleNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (4 ops.)

€1.3M

Latest filing published 25 Feb 2026 for Supernus Pharmaceuticals, INC.. Read the official filing

Filing timeline

BuySale

Charles W. Newhall III

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Charles W. Newhall III: trading record in brief

All filings by Charles W. Newhall III on record concern Supernus Pharmaceuticals, Inc., in the capacity of senior executive. In total, 13 filings cover trades dated from 19 February 2022 to 24 February 2026.

No open-market purchase appears, only 4 sales worth €1.3M. Other entries cover 5 share grants and 4 option exercises.

The latest filing, published on 25 February 2026, reports a share grant in Supernus Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.